Theraclion (EPA:ALTHE) this week released 2-year results from a trial of its Echopulse non-invasive ultrasound system for treating breast fibroadenoma. Study results were published in the March 2017 issue of the Journal of Therapeutic Ultrasound, the French company said. The 20 patient study examined the use of the Echopulse system, an ultrasound-guided high-intensity focused ultrasound device, in reducing […]
Clinical Trials
Avita shares rise on FDA nod for expanded ReCell trial
Avita Medical (ASX:AVH) today saw shares jump as much as 7% after the FDA approved an expansion to the number of patients that can be treated in a trial of its ReCell regenerative device. The ReCell device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and […]
7 medtech stories we missed this week: April 7, 2017
New studies for umbilical cord allografts and tumor targeting were published this week while another company received European CE Marking. Here are some medtech stories we missed this week but thought were still worth mentioning. 1. AMNIOX touts new umbilical cord study AMNIOX Medical announced that it has published the results of 3 studies that demonstrate […]
Bellerophon touts effects of inhaled nitric oxide in pulmonary arterial hypertension
Bellerophon Therapeutics (NSDQ:BLPH) presented data for its INOpulse nitric oxide device in patients with pulmonary arterial hypertension at the International Society of Heart and Lung Transplantation’s annual meeting. Researchers studied the effects of pulsed inhaled nitric oxide, delivered by the INOpulse device in 10 patients with pulmonary arterial hypertension both before and after exercise. The […]
ISHLT 2017: Medtronic touts thoracotomy study for Heartware HVAD
Medtronic (NYSE:MDT) this week presented results from the HVAD Lateral thoractomy study of its HVAD heart pump system in patients with end-stage heart failure, touting high survival rates and freedom from stroke. The study aimed to explore the use of the HVAD system delivered through a less-invasive thoracotomy procedure in patients with end-stage heart failure […]
Patients twice as likely to take anticoagulants with artificial intelligence platform
Researchers from the Stern Stroke Center at Montefiore Medical Center published trial results this week showing that stroke survivors were twice as likely to take anticoagulants when using an artificial intelligence platform compared to patients receiving standard therapies. The AI platform, AiCure, features software algorithms on smartphones that confirm patient identify, medication and drug ingestion. […]
Keystone Nano launches clinical trial for NanoLiposome cancer therapy
Keystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for solid tumors. Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that […]
ISHLT 2017: Less clotting, bleeding events for Abbott’s HeartMate 3
New 6-month data presented today on Abbott‘s (NYSE:ABT) HeartMate 3 left ventricular assist system indicated fewer adverse clotting and bleeding events than with its HearMate II. Data came from a 6-month analysis of its pivotal Momentum 3 trial, a randomized, non-blinded study which aimed to compare the new HeartMate 3 system to the previous-generation HeartMate II. Results […]
AcelRx touts data from Dsuvia pain relief trials
AcelRx Pharmaceuticals (NSDQ:ACRX) touted efficacy and safety data today for its pain reliever, Dsuvia. The company’s lead drug candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country. The 4 late-phase studies enrolled 480 patients total. In 2 randomized studies, enrolled patients underwent bunionectomy […]
SteadyMed studies accuracy and precision of PatchPump infusion system for Trevyent
SteadyMed (NSDQ:STDY) said yesterday that it finished a clinical study for its lead drug candidate, Trevyent. The pulmonary arterial hypertension treatment is a combination of treprostinil and the PatchPump prefilled, disposable infusion system. The San Ramon, Calif.-based company said it is on track to submit a New Drug Application for Trevyent in the 2nd quarter […]
ISHLT 2017: Medtronic HVAD trial misses primary endpoint, reports lowered stroke rates
Medtronic (NYSE:MDT) said today that results from the Endurance supplemental trial of its HVAD heart pump system did not meet its primary endpoint, but did report lowered stroke rates compared to standard treatment. The trial aimed to evaluate the use of the HVAD system, which it picked up along with HeartWare last year, as a destination […]